Value the standardized treatment of pediatric retinal diseases to improve its treatment level_Chinese Journal of Ocular Fundus Diseases

Authors：

 Zhang Guoming , Zhao Jinfeng

Shenzhen Eye Hospital Affiliated to Jinan University, Shenzhen Key Medical Discipline, Guangdong High-level Clinical Key Discipline, Shenzhen 518040, China;

Corresponding author：

Zhang Guoming, Email: zhang-guoming@163.com

Keywords：

Retinal Diseases/therapy; Child; Benchmarking; Editorial

DOI：

10.3760/cma.j.cn511434-20200806-00380

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, with the deepening of understanding of children's retinal diseases and the continuous updating of treatment techniques, the efficacy of children's retinal diseases has also been improved. Due to the particularity of the anatomical structure of the retina of children in the growth and development stage and the pathogenesis, clinical manifestations and outcomes of children's retinal diseases are different from those of adults, the principles of treatment of adult retinal diseases cannot be directly applied to children's retinal diseases. Cryotherapy, laser photocoagulation, intravitreal injection of anti-VEGF drugs, and vitreoretinal surgery are the main treatment methods for children's retinal diseases. However, there are still many problems in the selection of indications, equipment parameters, and treatment of complications. The treatment norms of the disease need to be further improved. Therefore, research on the treatment of children's retinal diseases, and the establishment of surgical standards and norms through expert consensus and other methods are helpful for the treatment of children's retinal diseases.

Citation： Zhang Guoming, Zhao Jinfeng. Value the standardized treatment of pediatric retinal diseases to improve its treatment level. Chinese Journal of Ocular Fundus Diseases, 2020, 36(8): 583-589. doi: 10.3760/cma.j.cn511434-20200806-00380 Copy

1.	赵培泉, 张琦, 许宇. 提高小儿视网膜疾病的认知水平, 推动我国小儿视网膜疾病研究的深入开展[J]. 中华眼底病杂志, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.Zhao PQ, Zhang Q, Xu Y. The diagnosis and treatment of pediatric retinal disease[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.
2.	张国明, 曾键. 深入研究儿童适宜眼底影像检查技术, 努力提高小儿视网膜疾病诊断水平[J]. 中华眼底病杂志, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.Zhang GM, Zeng J. Study pediatric fundus imaging techniques to improve the diagnosis of retinal diseases in children[J]. Chin J Ocul Fundus Dis, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.
3.	Zhao J, Wu Z, Lam W, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity[J/OL]. Br J Ophthalmol, 2020, 2020: E1[2020-02-12]. https://bjo.bmj.com/content/early/2020/02/12/bjophthalmol-2019-315520.long. DOI: 10.1136/bjophthalmol-2019-315520. [publishedonline ahead of print].
4.	中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Chinese Ocular Fundus Diseases Society, Chinese Ophthalmological Society, Chinese Medical Association. Guidelines for screening retinopathy of premature infants in China(2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
5.	赵培泉, 单海冬, 程朝晖, 等. 阈值前病变1型和阈值期早产儿视网膜病变的激光和冷冻治疗[J]. 中华眼底病杂志, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.Zhao PQ, Shan HD, Cheng CH, et al. Photocoagulation and cryotherapy for prethreshold type 1 and threshold disease of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.
6.	彭婕, 张琦, 龙新纯, 等. 色素失禁症的眼部表现及治疗[J]. 中华眼底病杂志, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.Peng J, Zhang Q, Long XC, et al. Ocular manifestations and treatment of pigment incontinence[J]. Chin J Ocul Fundus Dis, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.
7.	吴中耀, 杨华胜, 陈智聪, 等. 视网膜母细胞瘤的激光、冷冻和放射治疗[J]. 中华眼底病杂志, 1996, 12(1): 48-50, 82.Wu ZY, Yang HS, Chen ZC, et al. Laser, cryotherapy and radiotherapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 1996, 12(1): 48-50, 82.
8.	张国明, 曾键, 黄丽娜, 等. 广角数码儿童视网膜成像系统引导下激光光凝治疗早产儿视网膜病变[J]. 中华眼底病杂志, 2008, 24(1): 17-19.Zhang GM, Zeng J, Huang LN, et al. Wide-field digital pediatric retinal imaging system-assisted photocoagulation for retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2008, 24(1): 17-19.
9.	赵琦, 彭晓燕, 张永鹏, 等. 视网膜冷冻手术联合玻璃体注射曲安奈德治疗伴有渗出性视网膜脱离Coats病的初步观察[J]. 中华眼底病杂志, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.Zhao Q, Peng XY, Zhang YP, et al. Using cryotherapy and intravitreal triamcinolone injection to treat Coats' disease with exudative retinal detachment[J]. Chin J Ocul Fundus Dis, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.
10.	Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial[J]. JAMA Ophthalmol, 2014, 132(11): 1327-1333. DOI: 10.1001/jamaophthalmol.2014.2772.
11.	Sanghi G, Dogra MR, Das P, et al. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment[J]. Retina, 2009, 29(9): 1335-1339. DOI: 10.1097/IAE.0b013e3181a68f3a.
12.	Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
13.	张国明, 唐松, 曾键, 等. 早产儿视网膜病变激光光凝辅助玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab治疗临床疗效观察[J]. 中华眼底病杂志, 2012, 28(1): 18-21.Zhang GM, Tang S, Zeng J, et al. The clinical observation of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2012, 28(1): 18-21.
14.	Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone Ⅱ treatment-requiring retinopathy of prematurity[J]. Retina, 2017, 37(4): 710-717. DOI: 10.1097/IAE.0000000000001241.
15.	费萍, 张琦, 许宇, 等. 儿童牵牛花综合征并发视网膜脱离的临床特征及治疗效果观察[J]. 中华眼底病杂志, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.Fei P, Zhang Q, Xu Y, et al. Clinical analysis and management of pediatric retinal detachment associated with morning glory syndrome[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.
16.	赵培泉, 虞瑛青, 单海冬, 等. 家族性渗出性玻璃体视网膜病变治疗观察[J]. 中华眼底病杂志, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.Zhao PQ, Yu YQ, Shan HD, et al. Treatment for familial exudative vitreoretinopathy[J]. Chin J Ocul Fundus Dis, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.
17.	Shaikh S, Trese MT, Archer SM. Fluorescein angiographic findings in incontinentia pigmenti[J]. Retina, 2004, 24(4): 628-629. DOI: 10.1097/00006982-200408000-00025.
18.	Rishi P, Singh N, Rishi E. Retinopathy in incontinentia pigmenti[J]. Indian J Ophthalmol, 2019, 67(6): 940-942. DOI: 10.4103/ijo.IJO_760_18.
19.	Chen CJ, Han IC, Tian J, et al. Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti: analysis of peripheral vascular changes and incidence of retinal detachment[J]. JAMA Ophthalmol, 2015, 133(5): 542-548. DOI: 10.1001/jamaophthalmol.2015.22.
20.	Ni Y, Huang X, Ruan L, et al. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti[J]. J AAPOS, 2018, 22(4): 325-327. DOI: 10.1016/j.jaapos.2018.01.008.
21.	Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China[J]. Ophthalmology, 2017, 124(3): 408-409. DOI: 10.1016/j.ophtha.2016.10.032.
22.	Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone Ⅱ, stage 3 with plus disease[J]. BMC Ophthalmol, 2015, 15: 20. DOI: 10.1186/s12886-015-0001-7.
23.	VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
24.	Ho M, Yip WWK, Chan VCK, et al. Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child[J]. Retin Cases Brief Rep, 2017, 11(4): 352-355. DOI: 10.1097/ICB.0000000000000369.
25.	Lu YZ, Deng GD, Liu JH, et al. The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater[J]. Int J Ophthalmol, 2018, 11(6): 976-980. DOI: 10.18240/ijo.2018.06.13.
26.	姜华, 方倩, 邓海浪, 等. 经眼动脉灌注化学药物治疗视网膜母细胞瘤临床疗效观察[J]. 中华眼底病杂志, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.Jiang H, Fang Q, Deng HL, et al. Intra-arterial chemotherapy as secondly therapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.
27.	侯宪如, 程湧, 张琦, 等. 玻璃体腔注射卡铂联合贝伐单抗治疗难治型视网膜母细胞瘤的疗效观察[J]. 中华眼科杂志, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.Hou XR, Cheng Y, Zhang Q, et al. Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma[J]. Chin J Ophthalmol, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.
28.	Gan NY, Lam WC. Special considerations for pediatric vitreoretinal surgery[J]. Taiwan J Ophthalmol, 2018, 8(4): 237-242. DOI: 10.4103/tjo.tjo_83_18.
29.	Ling KP, Wu AL, Lai CC, et al. Short-term postoperative perfluoro-n-octane tamponade for pediatric recurrent retinal detachment[J]. Taiwan J Ophthalmol, 2018, 8(4): 249-252. DOI: 10.4103/tjo.tjo_100_18.
30.	Dyrda A, Català-Mora J, Rey A, et al. Macular hole after poppers (Alkyl Nitrate) inhalation in a child[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(11): 897-900. DOI: 10.3928/23258160-20181101-12.
31.	Savla LP, Nene A, Sutar S, et al. Spontaneous attachment of rhegmatogenous retinal detachment following vitrectomy for stage 4B retinopathy of prematurity and atypical retinal changes post-resolution[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(7): 544-547. DOI: 10.3928/23258160-20180628-13.
32.	Wood EH, Drenser KA, Capone A Jr. Diagnosis and management of familial exudative vitreoretinopathy: a lifelong, progressive, and often asymmetric disease[J/OL]. JAMA Ophthalmol, 2019, 2019: E1[2019-06-06]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2019.1484. DOI: 10.1001/jamaophthalmol.2019.1484. [publishedonline head of print].
33.	Liu J, Zhao P. Lamellar macular hole with lamellar hole-associated epiretinal proliferation in familial exudative vitreoretinopathy[J/OL]. Retin Cases Brief Rep, 2018, 2018: E1[2018-08-21]. https://doi.org/10.1097/ICB.0000000000000807. DOI: 10.1097/ICB.0000000000000807. [publishedonline ahead of print].
34.	Yeo DCM, Nagiel A, Yang U, et al. Endoscopy for pediatric retinal disease[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 200-207. DOI: 10.22608/APO.2018154.
35.	Wong SC, Lee TC, Heier JS, et al. Endoscopic vitrectomy[J]. Curr Opin Ophthalmol, 2014, 25(3): 195-206. DOI: 10.1097/ICU.0000000000000052.
36.	Yousef YA, Manna M, Khalil MB, et al. Surgical repair of rhegmatogenous retinal detachment in eyes harboring active retinoblastoma[J]. Ophthalmic Genet, 2016, 37(3): 314-317. DOI: 10.3109/13816810.2015.1046556.
37.	姜燕荣, 黎晓新, 殷春悦. 儿童孔源性视网膜脱离手术治疗特点及疗效分析[J]. 中华眼科杂志, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.Jiang YR, Li XX, Yin CY. Evaluation of treatment for retinal detachment in juveniles[J]. Chin J Ophthalmol, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.
38.	Papakostas TD, Vavvas D. Postoperative complications of scleral buckling[J]. Semin Ophthalmol, 2018, 33(1): 70-74. DOI: 10.1080/08820538.2017.1353816.
39.	Reddy MA, Naeem Z, Duncan C, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma[J]. Br J Ophthalmol, 2017, 101(12): 1704-1708. DOI: 10.1136/bjophthalmol-2017-310294.
40.	Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds[J]. Br J Ophthalmol, 2019, 103(4): 488-493. DOI: 10.1136/bjophthalmol-2018-312037.
41.	高翔, 王海燕, 王雨生. 复发或顽固性眼内视网膜母细胞瘤玻璃体腔化学药物治疗的现状与进展[J]. 中华眼底病杂志, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.Gao X, Wang HY, Wang YS. The status and progress of intravitreal chemotherapy for resistant or recurrent retinoblastoma[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.
42.	魏文斌, 周楠. 重视视网膜母细胞瘤的规范化治疗, 提升视网膜母细胞瘤的治疗水平[J]. 中华眼底病杂志, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.Wei WB, Zhou N. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.
43.	DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina[J]. J Clin Invest, 2018, 128(6): 2177-2188. DOI: 10.1172/JCI120429.
44.	杜洋, 苏冠方. 家族性渗出性玻璃体视网膜病变致病基因研究进展[J]. 眼科新进展, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.Du Y, Su GF. Recent advances in pathogenic genes of familial exudative vitreoretinopathy[J]. Rec Adv Ophthalmol, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.
45.	Hassall MM, Barnard AR, MacLaren RE. Gene therapy for color blindness[J]. Yale J Biol Med, 2017, 90(4): 543-551.
46.	Lu LJ, Liu J, Adelman RA. Novel therapeutics for stargardt disease[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1057-1062. DOI: 10.1007/s00417-017-3619-8.
47.	Parker MA, Choi D, Erker LR, et al. Test-retest variability of functional and structural parameters in patients with stargardt disease participating in the SAR422459 gene therapy trial[J]. Transl Vis Sci Technol, 2016, 5(5): 10. DOI: 10.1167/tvst.5.5.10.
48.	Fischer MD, Michalakis S, Wilhelm B, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial[J]. JAMA Ophthalmol, 2020, 138(6): 1-9. DOI: 10.1001/jamaophthalmol.2020.1032.
49.	Bhattacharya S, Gangaraju R, Chaum E. Recent advances in retinal stem cell therapy[J]. Curr Mol Biol Rep, 2017, 3(3): 172-182. DOI: 10.1007/s40610-017-0069-3.
50.	Bashar AE, Metcalfe AL, Viringipurampeer IA, et al. An ex vivo gene therapy approach in X-linked retinoschisis[J]. Mol Vis, 2016, 22: 718-733.
51.	Ma QQ, Liu FY, Shi M, et al. Bone marrow mesenchymal stem cells modified by angiogenin-1 promotes tissue repair in mice with oxygen-induced retinopathy of prematurity by promoting retinal stem cell proliferation and differentiation[J]. J Cell Physiol, 2019, 234(11): 21027-21038. DOI: 10.1002/jcp.28706.
52.	韩如意, 金子兵. 遗传性眼底病基因和干细胞治疗趋势与面临的挑战和机遇[J]. 中华眼底病杂志, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.Han RY, Jin ZB. Progress and opportunities of gene and stem cell therapy on hereditary ocular fundus diseases[J]. Chin J Ocul Fundus Dis, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.
53.	Xu Y, Lu X, Hu Y, et al. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice[J/OL]. J Pineal Res, 2018, 64(4): 12473[2018-03-08]. https://doi.org/10.1111/jpi.12473. DOI: 10.1111/jpi.12473.

1. 赵培泉, 张琦, 许宇. 提高小儿视网膜疾病的认知水平, 推动我国小儿视网膜疾病研究的深入开展[J]. 中华眼底病杂志, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.Zhao PQ, Zhang Q, Xu Y. The diagnosis and treatment of pediatric retinal disease[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 1-5. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.001.
2. 张国明, 曾键. 深入研究儿童适宜眼底影像检查技术, 努力提高小儿视网膜疾病诊断水平[J]. 中华眼底病杂志, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.Zhang GM, Zeng J. Study pediatric fundus imaging techniques to improve the diagnosis of retinal diseases in children[J]. Chin J Ocul Fundus Dis, 2016, 32(3): 237-242. DOI: 10.3760/cma.j.issn.1005-1015.2016.03.003.
3. Zhao J, Wu Z, Lam W, et al. Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity[J/OL]. Br J Ophthalmol, 2020, 2020: E1[2020-02-12]. https://bjo.bmj.com/content/early/2020/02/12/bjophthalmol-2019-315520.long. DOI: 10.1136/bjophthalmol-2019-315520. [publishedonline ahead of print].
4. 中华医学会眼科学分会眼底病学组. 中国早产儿视网膜病变筛查指南(2014年)[J]. 中华眼科杂志, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.Chinese Ocular Fundus Diseases Society, Chinese Ophthalmological Society, Chinese Medical Association. Guidelines for screening retinopathy of premature infants in China(2014)[J]. Chin J Ophthalmol, 2014, 50(12): 933-935. DOI: 10.3760/cma.j.issn.0412-4081.2014.12.017.
5. 赵培泉, 单海冬, 程朝晖, 等. 阈值前病变1型和阈值期早产儿视网膜病变的激光和冷冻治疗[J]. 中华眼底病杂志, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.Zhao PQ, Shan HD, Cheng CH, et al. Photocoagulation and cryotherapy for prethreshold type 1 and threshold disease of retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2005, 21(5): 278-281. DOI: 10.3760/j.issn:1005-1015.2005.05.003.
6. 彭婕, 张琦, 龙新纯, 等. 色素失禁症的眼部表现及治疗[J]. 中华眼底病杂志, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.Peng J, Zhang Q, Long XC, et al. Ocular manifestations and treatment of pigment incontinence[J]. Chin J Ocul Fundus Dis, 2015, 31(3): 307-309. DOI: 10.3760/cma.j.issn.1005-1015.2015.03.028.
7. 吴中耀, 杨华胜, 陈智聪, 等. 视网膜母细胞瘤的激光、冷冻和放射治疗[J]. 中华眼底病杂志, 1996, 12(1): 48-50, 82.Wu ZY, Yang HS, Chen ZC, et al. Laser, cryotherapy and radiotherapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 1996, 12(1): 48-50, 82.
8. 张国明, 曾键, 黄丽娜, 等. 广角数码儿童视网膜成像系统引导下激光光凝治疗早产儿视网膜病变[J]. 中华眼底病杂志, 2008, 24(1): 17-19.Zhang GM, Zeng J, Huang LN, et al. Wide-field digital pediatric retinal imaging system-assisted photocoagulation for retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2008, 24(1): 17-19.
9. 赵琦, 彭晓燕, 张永鹏, 等. 视网膜冷冻手术联合玻璃体注射曲安奈德治疗伴有渗出性视网膜脱离Coats病的初步观察[J]. 中华眼底病杂志, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.Zhao Q, Peng XY, Zhang YP, et al. Using cryotherapy and intravitreal triamcinolone injection to treat Coats' disease with exudative retinal detachment[J]. Chin J Ocul Fundus Dis, 2010, 26(6): 540-543. DOI: 10.3760/cma.j.issn.1005-1015.2010.06.11.
10. Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial[J]. JAMA Ophthalmol, 2014, 132(11): 1327-1333. DOI: 10.1001/jamaophthalmol.2014.2772.
11. Sanghi G, Dogra MR, Das P, et al. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment[J]. Retina, 2009, 29(9): 1335-1339. DOI: 10.1097/IAE.0b013e3181a68f3a.
12. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity[J]. N Engl J Med, 2011, 364(7): 603-615. DOI: 10.1056/NEJMoa1007374.
13. 张国明, 唐松, 曾键, 等. 早产儿视网膜病变激光光凝辅助玻璃体腔注射抗血管内皮生长因子单克隆抗体bevacizumab治疗临床疗效观察[J]. 中华眼底病杂志, 2012, 28(1): 18-21.Zhang GM, Tang S, Zeng J, et al. The clinical observation of bevacizumab intravitreal injection as adjunctive treatment for laser coagulation to treat retinopathy of prematurity[J]. Chin J Ocul Fundus Dis, 2012, 28(1): 18-21.
14. Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone Ⅱ treatment-requiring retinopathy of prematurity[J]. Retina, 2017, 37(4): 710-717. DOI: 10.1097/IAE.0000000000001241.
15. 费萍, 张琦, 许宇, 等. 儿童牵牛花综合征并发视网膜脱离的临床特征及治疗效果观察[J]. 中华眼底病杂志, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.Fei P, Zhang Q, Xu Y, et al. Clinical analysis and management of pediatric retinal detachment associated with morning glory syndrome[J]. Chin J Ocul Fundus Dis, 2014, 30(1): 46-49. DOI: 10.3760/cma.j.issn.1005-1015.2014.01.012.
16. 赵培泉, 虞瑛青, 单海冬, 等. 家族性渗出性玻璃体视网膜病变治疗观察[J]. 中华眼底病杂志, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.Zhao PQ, Yu YQ, Shan HD, et al. Treatment for familial exudative vitreoretinopathy[J]. Chin J Ocul Fundus Dis, 2006, 22(5): 302-304. DOI: 10.3760/j.issn:1005-1015.2006.05.005.
17. Shaikh S, Trese MT, Archer SM. Fluorescein angiographic findings in incontinentia pigmenti[J]. Retina, 2004, 24(4): 628-629. DOI: 10.1097/00006982-200408000-00025.
18. Rishi P, Singh N, Rishi E. Retinopathy in incontinentia pigmenti[J]. Indian J Ophthalmol, 2019, 67(6): 940-942. DOI: 10.4103/ijo.IJO_760_18.
19. Chen CJ, Han IC, Tian J, et al. Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti: analysis of peripheral vascular changes and incidence of retinal detachment[J]. JAMA Ophthalmol, 2015, 133(5): 542-548. DOI: 10.1001/jamaophthalmol.2015.22.
20. Ni Y, Huang X, Ruan L, et al. Intravitreal injection of ranibizumab in severe retinopathy of incontinentia pigmenti[J]. J AAPOS, 2018, 22(4): 325-327. DOI: 10.1016/j.jaapos.2018.01.008.
21. Feng J, Qian J, Jiang Y, et al. Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China[J]. Ophthalmology, 2017, 124(3): 408-409. DOI: 10.1016/j.ophtha.2016.10.032.
22. Menke MN, Framme C, Nelle M, et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone Ⅱ, stage 3 with plus disease[J]. BMC Ophthalmol, 2015, 15: 20. DOI: 10.1186/s12886-015-0001-7.
23. VanderVeen DK, Melia M, Yang MB, et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology[J]. Ophthalmology, 2017, 124(5): 619-633. DOI: 10.1016/j.ophtha.2016.12.025.
24. Ho M, Yip WWK, Chan VCK, et al. Successful treatment of refractory proliferative retinopathy of incontinentia pigmenti by intravitreal ranibizumab as adjunct therapy in a 4-year-old child[J]. Retin Cases Brief Rep, 2017, 11(4): 352-355. DOI: 10.1097/ICB.0000000000000369.
25. Lu YZ, Deng GD, Liu JH, et al. The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater[J]. Int J Ophthalmol, 2018, 11(6): 976-980. DOI: 10.18240/ijo.2018.06.13.
26. 姜华, 方倩, 邓海浪, 等. 经眼动脉灌注化学药物治疗视网膜母细胞瘤临床疗效观察[J]. 中华眼底病杂志, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.Jiang H, Fang Q, Deng HL, et al. Intra-arterial chemotherapy as secondly therapy for retinoblastoma[J]. Chin J Ocul Fundus Dis, 2017, 33(6): 612-615. DOI: 10.3760/cma.j.issn.1005-1015.2017.06.014.
27. 侯宪如, 程湧, 张琦, 等. 玻璃体腔注射卡铂联合贝伐单抗治疗难治型视网膜母细胞瘤的疗效观察[J]. 中华眼科杂志, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.Hou XR, Cheng Y, Zhang Q, et al. Efficacy of intravitreal carboplatin plus bevacizumab in refractory retinoblastoma[J]. Chin J Ophthalmol, 2015, 51(2): 126-129. DOI: 10.3760/cma.j.issn.0412-4081.2015.02.013.
28. Gan NY, Lam WC. Special considerations for pediatric vitreoretinal surgery[J]. Taiwan J Ophthalmol, 2018, 8(4): 237-242. DOI: 10.4103/tjo.tjo_83_18.
29. Ling KP, Wu AL, Lai CC, et al. Short-term postoperative perfluoro-n-octane tamponade for pediatric recurrent retinal detachment[J]. Taiwan J Ophthalmol, 2018, 8(4): 249-252. DOI: 10.4103/tjo.tjo_100_18.
30. Dyrda A, Català-Mora J, Rey A, et al. Macular hole after poppers (Alkyl Nitrate) inhalation in a child[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(11): 897-900. DOI: 10.3928/23258160-20181101-12.
31. Savla LP, Nene A, Sutar S, et al. Spontaneous attachment of rhegmatogenous retinal detachment following vitrectomy for stage 4B retinopathy of prematurity and atypical retinal changes post-resolution[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(7): 544-547. DOI: 10.3928/23258160-20180628-13.
32. Wood EH, Drenser KA, Capone A Jr. Diagnosis and management of familial exudative vitreoretinopathy: a lifelong, progressive, and often asymmetric disease[J/OL]. JAMA Ophthalmol, 2019, 2019: E1[2019-06-06]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2019.1484. DOI: 10.1001/jamaophthalmol.2019.1484. [publishedonline head of print].
33. Liu J, Zhao P. Lamellar macular hole with lamellar hole-associated epiretinal proliferation in familial exudative vitreoretinopathy[J/OL]. Retin Cases Brief Rep, 2018, 2018: E1[2018-08-21]. https://doi.org/10.1097/ICB.0000000000000807. DOI: 10.1097/ICB.0000000000000807. [publishedonline ahead of print].
34. Yeo DCM, Nagiel A, Yang U, et al. Endoscopy for pediatric retinal disease[J]. Asia Pac J Ophthalmol (Phila), 2018, 7(3): 200-207. DOI: 10.22608/APO.2018154.
35. Wong SC, Lee TC, Heier JS, et al. Endoscopic vitrectomy[J]. Curr Opin Ophthalmol, 2014, 25(3): 195-206. DOI: 10.1097/ICU.0000000000000052.
36. Yousef YA, Manna M, Khalil MB, et al. Surgical repair of rhegmatogenous retinal detachment in eyes harboring active retinoblastoma[J]. Ophthalmic Genet, 2016, 37(3): 314-317. DOI: 10.3109/13816810.2015.1046556.
37. 姜燕荣, 黎晓新, 殷春悦. 儿童孔源性视网膜脱离手术治疗特点及疗效分析[J]. 中华眼科杂志, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.Jiang YR, Li XX, Yin CY. Evaluation of treatment for retinal detachment in juveniles[J]. Chin J Ophthalmol, 2001, 37(3): 167-170. DOI: 10.3760/j:issn:0412-4081.2001.03.003.
38. Papakostas TD, Vavvas D. Postoperative complications of scleral buckling[J]. Semin Ophthalmol, 2018, 33(1): 70-74. DOI: 10.1080/08820538.2017.1353816.
39. Reddy MA, Naeem Z, Duncan C, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma[J]. Br J Ophthalmol, 2017, 101(12): 1704-1708. DOI: 10.1136/bjophthalmol-2017-310294.
40. Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds[J]. Br J Ophthalmol, 2019, 103(4): 488-493. DOI: 10.1136/bjophthalmol-2018-312037.
41. 高翔, 王海燕, 王雨生. 复发或顽固性眼内视网膜母细胞瘤玻璃体腔化学药物治疗的现状与进展[J]. 中华眼底病杂志, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.Gao X, Wang HY, Wang YS. The status and progress of intravitreal chemotherapy for resistant or recurrent retinoblastoma[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 449-453. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.028.
42. 魏文斌, 周楠. 重视视网膜母细胞瘤的规范化治疗, 提升视网膜母细胞瘤的治疗水平[J]. 中华眼底病杂志, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.Wei WB, Zhou N. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome[J]. Chin J Ocul Fundus Dis, 2020, 36(6): 413-418. DOI: 10.3760/cma.j.cn511434-20200520-00209.
43. DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina[J]. J Clin Invest, 2018, 128(6): 2177-2188. DOI: 10.1172/JCI120429.
44. 杜洋, 苏冠方. 家族性渗出性玻璃体视网膜病变致病基因研究进展[J]. 眼科新进展, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.Du Y, Su GF. Recent advances in pathogenic genes of familial exudative vitreoretinopathy[J]. Rec Adv Ophthalmol, 2015, 35(9): 887-890, 895. DOI: 10.13389/j.cnki.rao.2015.0243.
45. Hassall MM, Barnard AR, MacLaren RE. Gene therapy for color blindness[J]. Yale J Biol Med, 2017, 90(4): 543-551.
46. Lu LJ, Liu J, Adelman RA. Novel therapeutics for stargardt disease[J]. Graefe's Arch Clin Exp Ophthalmol, 2017, 255(6): 1057-1062. DOI: 10.1007/s00417-017-3619-8.
47. Parker MA, Choi D, Erker LR, et al. Test-retest variability of functional and structural parameters in patients with stargardt disease participating in the SAR422459 gene therapy trial[J]. Transl Vis Sci Technol, 2016, 5(5): 10. DOI: 10.1167/tvst.5.5.10.
48. Fischer MD, Michalakis S, Wilhelm B, et al. Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial[J]. JAMA Ophthalmol, 2020, 138(6): 1-9. DOI: 10.1001/jamaophthalmol.2020.1032.
49. Bhattacharya S, Gangaraju R, Chaum E. Recent advances in retinal stem cell therapy[J]. Curr Mol Biol Rep, 2017, 3(3): 172-182. DOI: 10.1007/s40610-017-0069-3.
50. Bashar AE, Metcalfe AL, Viringipurampeer IA, et al. An ex vivo gene therapy approach in X-linked retinoschisis[J]. Mol Vis, 2016, 22: 718-733.
51. Ma QQ, Liu FY, Shi M, et al. Bone marrow mesenchymal stem cells modified by angiogenin-1 promotes tissue repair in mice with oxygen-induced retinopathy of prematurity by promoting retinal stem cell proliferation and differentiation[J]. J Cell Physiol, 2019, 234(11): 21027-21038. DOI: 10.1002/jcp.28706.
52. 韩如意, 金子兵. 遗传性眼底病基因和干细胞治疗趋势与面临的挑战和机遇[J]. 中华眼底病杂志, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.Han RY, Jin ZB. Progress and opportunities of gene and stem cell therapy on hereditary ocular fundus diseases[J]. Chin J Ocul Fundus Dis, 2018, 34(6): 519-525. DOI: 10.3760/cma.j.issn.1005-1015.2018.06.001.
53. Xu Y, Lu X, Hu Y, et al. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1α-VEGF pathway in oxygen-induced retinopathy mice[J/OL]. J Pineal Res, 2018, 64(4): 12473[2018-03-08]. https://doi.org/10.1111/jpi.12473. DOI: 10.1111/jpi.12473.

Next Article
Clinical observations of micro-incision vitrectomy surgery for retinopathy of prematurity with early intervention failure

Chinese Journal of Ocular Fundus Diseases

Value the standardized treatment of pediatric retinal diseases to improve its treatment level

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content